autologous tumor mRNA-transfected dendritic cell vaccine (Oslo University Hospital)

This is an investigational personalized cancer vaccine developed by researchers at Oslo University Hospital for the treatment of advanced malignant melanoma. The therapy involves harvesting a patient's monocytes via leukapheresis, differentiating them into dendritic cells, and then transfecting these cells with mRNA extracted from the patient's own tumor tissue using electroporation. These matured, mRNA-loaded dendritic cells are then re-administered to the patient (intradermally or intranodally) to stimulate a T-cell-mediated immune response against a broad range of tumor-associated antigens and patient-specific neoantigens. Clinical evaluation in Phase I/II trials has demonstrated the vaccine's safety and ability to elicit immunological responses, with some evidence of clinical benefit in patients with stage IV disease.

Other names

mRNA-transfected DC vaccineautologous tumor mRNA-transfected DCsDendritic Cells (DC) malignant melanoma